The times of robots being primarily restricted to manufacturing functions are lengthy gone—the trade is increasing quickly and turning into built-in into many various sectors due to fast developments in AI and automation. Analysts count on this to result in main development for the trade within the years to return, with an anticipated CAGR of greater than 15% within the coming seven years to achieve a measurement of practically $170 billion globally by 2032.
As with AI and different fast-changing expertise areas, robotics is residence to each extra established corporations which might be venturing into the house—Japanese conglomerate Mitsubishi and even main tech corporations like NVIDIA Corp. (NASDAQ:) are linked with the robotics trade, for instance—in addition to smaller specialised corporations. Because the robotics panorama shifts, it is possible that a few of these smaller names might emerge as more and more necessary gamers.
Although time will inform how the robotics house develops, three underrated corporations which might be price keeping track of embody AeroVironment Inc. (NASDAQ:), Cognex Corp. (NASDAQ:), and Myomo Inc. (NYSE:).
1. AeroVironment: Good Positioning For Navy Purposes
AeroVironment is a protection firm growing and manufacturing drones and associated robotics programs, amongst different programs for army use. The corporate’s merchandise are experiencing surging demand as world political tensions enhance, in addition to fight tendencies towards unmanned autos and the mixing of AI into battle eventualities. The corporate’s loitering programs—which permit unmanned programs to stay engaged whereas undetected till an acceptable time for activation—have been particularly standard. AeroVironment introduced in mid-January 2025 that it had acquired a second supply order from the U.S. Military for a long-term contract with a ceiling worth of practically $1 billion.
AeroVironment’s most up-to-date quarter noticed a 4% year-over-year enhance in income to almost $189 million and a 25% sequential enhance in funded backlog. Additional, the corporate’s November 2024 acquisition of house and protection tech agency BlueHalo is more likely to proceed to bear fruit because it bolsters AeroVironment’s expertise capabilities, partnerships, and product record.
2. Cognex: Broadly Relevant Machine Imaginative and prescient Instruments
Robots have lengthy been utilized in manufacturing and distribution settings, however Cognex’s machine imaginative and prescient merchandise are revolutionizing their functions in these areas. Amongst different choices, its DataMan barcode readers are broadly helpful throughout industries, permitting will increase in operational effectivity for a lot of settings through which barcode scanning takes place.
In some methods, Cognex has but to take off from an funding standpoint. The corporate’s revenues have remained largely stagnant, and its 2023 buy of Moritex was expensive. Nonetheless, Cognex has a robust money place, which can purchase it time for its newest merchandise to achieve their full potential. Shares of CGNX are up about 11% within the final yr via Jan. 31, 2025, however down relative to a spike in July. Although they continue to be dear, it could possibly be a time to purchase on a relative dip. Based mostly on consensus estimates, analysts count on the worth of CGNX inventory to rise by about 20%.
3. Myomo: Analysts See Almost 38% Upside
Myomo is a wearable medical gadget firm manufacturing myoelectric orthotics, together with braces, to help stroke victims in regaining movement and management over their limbs. The corporate has discovered a major foothold with its merchandise, with income surging by 81% year-over-year in the latest quarter. Orders, backlog, and variety of people within the affected person pipeline have been additionally up considerably over that point interval, additional reflecting the recognition and Myomo’s merchandise.
A problem for Myomo is profitability. The agency stays unprofitable, however its gross margin is enhancing significantly—by 670 foundation factors to 75.4% within the final quarter. Whereas the worldwide orthotics market is estimated at near $7 billion, it’s also established with legacy corporations, presenting an uphill battle for Myomo to achieve market share. Nonetheless, its merchandise are favorably categorized for the needs of Medicare reimbursements, making Myomo more and more accessible to potential sufferers.
Myomo’s current $15-million public providing is anticipated to spice up promoting bills and worker headcount in a bid to arrange for elevated demand and income development. 4 analysts have rated Myomo a Purchase, seeing upside potential of practically 38% based mostly on the share value as of January 31, 2025.
Unique Publish
